Jeffrey Osterman is Global Co-Head of Intellectual Property & Technology Transactions and Chair of Life Sciences Licensing & Collaboration Transactions.
Osterman regularly advises major pharmaceutical companies in connection with licensing and collaboration agreements and manufacturing and supply arrangements. He has significant experience in numerous transactions involving novel therapeutic modalities, including genetic medicine and AI-assisted target and drug discovery.
Osterman also regularly leads the technology and intellectual property aspects of major corporate transactions, including commercial arrangements associated with such transactions; and advises on the treatment of intellectual property matters in bankruptcy cases.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Global IP Lawyers | 2026 | Life Sciences, Licensing, Tech Transactions |
| The 2026 Lawdragon 500 Leading Dealmakers in America | 2026 | Technology & IP Transactions |
| The Inaugural Lawdragon 500 Leading Global IP Lawyers | 2025 | Life Sciences, Licensing, Tech Transactions |
Osterman’s experience includes:
- Alkermes in its $2.3 billion acquisition of Avadel Pharmaceuticals
- DRI Healthcare Trust on the IP aspects of its acquisition of a tiered royalty interest in the U.S. net sales of two treatments for chronic thyroid eye disease from Viridian Therapeutics, for an aggregate purchase price of up to $300 million
- Eli Lilly in dozens of transactions, collaboration and license agreements with numerous companies involving novel therapeutic modalities, including:
- in its up to $2.4 billion acquisition of Orna Therapeutics, a biotechnology company dedicated to in vivo CAR-T engineering of immune cells
- in its up to $2.6 billion licensing and joint research agreement with ABL Bio for its proprietary blood-brain barrier shuttle platform known as Grabody-B, and a related equity investment
- in its agreement with Insilico, a biotechnology company with a proprietary artificial intelligence drug discovery platform, to leverage Insilico’s platform in order to discover and develop products for the treatment of pathogens resistant to current antibiotics
- as primary outside counsel in handling transactions addressing the global COVID-19 pandemic
- in collaboration agreements with AbCellera, a discoverer and developer of therapeutic antibodies which had identified antibodies against COVID-19 within 11 days of the first U.S. infection, and which became an early developer of monoclonal antibody therapy for the virus and emerging variants
- an evaluation and option agreement with Sangamo Therapeutics, granting Lilly the rights to employ STAC-BBB, Sangamo’s novel proprietary capsid, to advance potential treatments for neurological diseases
- GSK in its:
- up-to-$690 million exclusive licensing agreement with Alfasigma S.p.A.
- strategic partnership with LTZ Therapeutics to advance the development of novel myeloid cell engagers (MCEs) to address significant unmet need in oncology
- Metsera in its $10 billion sale to Pfizer, following a series of competing bids for the company by Pfizer and Novo Nordisk
- Progeria Research Foundation with respect to licensing agreements for therapies for Progeria